NCT00393965View on ClinicalTrials.gov

Multiple Dose Study of MPC-6827 in Subjects With Refractory Brain Metastases

PHASE1CompletedINTERVENTIONAL

Enrollment

18

Participants

Timeline

Start Date

December 31, 2005

Primary Completion Date

August 31, 2007

Study Completion Date

February 29, 2008

Conditions

Brain Neoplasms

Interventions

DRUG

MPC-6827

2-hour IV infusion given once weekly for 3 consecutive weeks on a 28-day cycle.

Trial Locations (1)

77030

MD Anderson Cancer Center, Houston

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Myrexis Inc.

INDUSTRY

NCT00393965 - Multiple Dose Study of MPC-6827 in Subjects With Refractory Brain Metastases | Biotech Hunter | Biotech Hunter